MDPI and ACS Style
Descourt, R.; Pérol, M.; Rousseau-Bussac, G.; Planchard, D.; Mennecier, B.; Wislez, M.; Cadranel, J.; Cortot, A.B.; Guisier, F.; Galland, L.;
et al. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers 2022, 14, 1751.
https://doi.org/10.3390/cancers14071751
AMA Style
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L,
et al. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers. 2022; 14(7):1751.
https://doi.org/10.3390/cancers14071751
Chicago/Turabian Style
Descourt, Renaud, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loïck Galland,
and et al. 2022. "Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study" Cancers 14, no. 7: 1751.
https://doi.org/10.3390/cancers14071751